

UC San Diego

UC San Diego Previously Published Works

Title

Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint

Permalink

<https://escholarship.org/uc/item/4927w18x>

Journal

Alzheimer's Research & Therapy, 14(1)

ISSN

1758-9193

Authors

Thomas, Kelsey R
Weigand, Alexandra J
Edwards, Lauren C
et al.

Publication Date

2022

DOI

10.1186/s13195-022-01060-1

Peer reviewed

RESEARCH

Open Access



Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint

Kelsey R. Thomas^{1,2*}, Alexandra J. Weigand³, Lauren C. Edwards³, Emily C. Edmonds⁴, Katherine J. Bangen^{1,2}, Gema Ortiz¹, Kayla S. Walker^{1,5}, Mark W. Bondi^{2,6} and for the Alzheimer's Disease Neuroimaging Initiative

Abstract

Background: The 2018 NIA-AA Alzheimer's Disease (AD) Research Framework states that subtle cognitive decline in cognitively unimpaired individuals can be measured by subjective reports or evidence of objective decline on neuropsychological measures. Both subjective memory complaint (SMC) and objective subtle cognitive decline (Obj-SCD) have been shown to be associated with future cognitive decline and AD biomarkers. We examined whether there are differences in tau PET levels between (a) SMC– vs. SMC+ participants, (b) Obj-SCD– vs. Obj-SCD+ participants, and (c) participants with overlapping vs. discrepant SMC and Obj-SCD classifications.

Methods: Cognitively unimpaired participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI; $n = 236$) were classified at baseline as positive or negative for SMC (SMC– $n = 77$; SMC+ $n = 159$) based on the first 12 items of the Cognitive Change Index and/or classified as positive or negative for Obj-SCD (Obj-SCD– $n = 173$; Obj-SCD+ $n = 63$) based on previously defined neuropsychological criteria. Analyses of covariance, adjusting for age, sex, APOE $\epsilon 4$ carrier status, and pulse pressure, examined the group differences in tau PET (AV-1451) using a composite standardized uptake variable ratio (SUVR) for regions consistent with Braak stage III/IV. The chi-squared tests examined the tau positivity rates across the groups.

Results: Obj-SCD+ participants had higher tau continuous SUVR levels ($p = .035$, $\eta_p^2 = .019$) and higher rates of tau positivity (15.8% Obj-SCD– vs. 30.2% Obj-SCD+) than Obj-SCD– participants. Neither tau levels ($p = .381$, $\eta_p^2 = .003$) nor rates of tau positivity (18.2% SMC– and 20.1% SMC+) differed between the SMC groups. There was very little agreement between SMC and Obj-SCD classifications (42%; $\kappa = 0.008$, $p = .862$). Participants who were Obj-SCD+ without SMC had the highest tau PET levels and differed from participants who were SMC+ without Obj-SCD ($p = .022$). Tau levels in participants with both SMC and Obj-SCD did not differ from those with only Obj-SCD ($p = .216$). Tau positivity rates across the SMC-/Obj-SCD–, SMC+/Obj-SCD–, SMC-/Obj-SCD+, and SMC+/Obj-SCD+ groups were 10.5%, 18.1%, 40.0%, and 25.6%, respectively.

Conclusion: Participants with Obj-SCD had a greater tau PET burden than those without Obj-SCD, but SMC was not associated with higher tau levels. The combination of SMC and Obj-SCD did not have higher tau levels than Obj-SCD alone. Findings add to the evidence that the Obj-SCD classification is associated with AD biomarkers and faster

*Correspondence: kthomas@health.ucsd.edu

¹ Research Service, VA San Diego Healthcare System, Building 13, 3350 La Jolla Village Drive (151), San Diego, CA 92161, USA
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

cognitive decline in ADNI participants, but further work is needed to validate this approach in more representative/diverse cohorts.

Keywords: Subjective memory concern, Subjective memory complaints, Subtle cognitive decline, Neuropsychology, Tau PET, Biomarkers, Preclinical Alzheimer's disease

Introduction

Research on Alzheimer's disease (AD) has continued to move toward earlier detection, as intervention and prevention of AD prior to widespread neurodegeneration has become a primary goal [1]. Within the 2018 NIA-AA AD Research Framework, clinical stage 2 recognizes that someone can be cognitively unimpaired (CU) but experience subtle cognitive decline, in contrast to stage 1 in which someone is CU with no indication of subtle cognitive changes. According to this framework, subtle cognitive decline can be measured by the subjective report of cognitive decline or evidence of objective decline using neuropsychological measures [2]. The best method for identifying subtle cognitive decline remains unknown, as both subjective and "objective" (i.e., neuropsychological) approaches have been shown to be associated with future cognitive decline and AD biomarkers. While many studies have examined the associations of subjective cognitive decline—especially subjective memory concerns (SMC)—and objective subtle cognitive decline (Obj-SCD) with amyloid [3–7], there has been limited research examining the associations of these classifications with *in vivo* measures of tau, particularly tau positron emission tomography (PET).

Subjective cognitive decline, and SMC in particular, has received significant attention, particularly since Jessen and colleagues published the conceptual framework for subjective cognitive decline in 2014 [8]. Importantly, this cognitive marker has the potential to be an extremely simple and cost-effective way to identify people at risk for future AD-related declines relative to many biomarker methods. Subjective cognitive decline is defined as a self-experienced decline in cognition relative to previous cognitive functioning that is not due to an acute event, psychiatric disease, medical disorder, medication, or substance use [8]. Evidence remains mixed regarding the relationship between subjective cognitive decline and risk of progression to mild cognitive impairment (MCI)/dementia. Although several studies have demonstrated associations between subjective cognitive decline and objective cognitive performance [9–11], other studies show that additional factors such as clinic vs. community-based samples, subclinical depressive/anxiety symptoms, physical health conditions, and how subjective cognitive decline is measured can impact the degree to which an individual's report of cognitive decline is associated with

AD pathology or future progression to MCI/dementia [12–16]. The subjective decline in memory in particular may be a useful marker of future decline in objective measures of cognition [17]. Therefore, consistent with the approach used in the Alzheimer's Disease Neuroimaging Initiative (ADNI), we specifically examined SMC as a marker of subjective cognitive decline.

Beyond subjective cognitive decline, there have been efforts to study the objective, sensitive neuropsychological measures that capture the earliest cognitive changes associated with AD pathology. Several studies have shown that subtle cognitive changes emerge much earlier than proposed by the amyloid cascade hypothesis [18], but these early changes have not been consistently captured due to the measures that are often used (e.g., cognitive screeners and clinical rating scales), which have poor sensitivity to detect very early changes [19, 20]. One approach to classifying subtle cognitive changes in the preclinical phase of AD that we have previously developed involves using sensitive neuropsychological measures and an actuarial definition that balances diagnostic sensitivity and specificity [4, 20, 21]. Objective subtle cognitive decline (Obj-SCD), not to be confused with subjective cognitive decline, uses both sensitive neuropsychological total scores and process/error scores, which capture how efficiently a neuropsychological test is performed and the types of errors that are produced. Obj-SCD status has been associated with faster progression to MCI/dementia, declines in everyday functioning, faster β -amyloid ($A\beta$) accumulation, faster increases in plasma p-tau181 levels, faster entorhinal cortex atrophy, and altered cerebral blood flow and functional MRI patterns [3, 4, 22–25]. However, the relationship between Obj-SCD and tau PET is unknown.

While the field continues to focus heavily on preclinical accumulation of $A\beta$, tau has a stronger relationship with cognitive decline than $A\beta$ [26, 27], making it a key linking marker during this pre-MCI phase given that it is ultimately the cognitive changes and resulting functional difficulties that impact the lives of patients and families [28]. Thus, we examined the tau PET differences in (a) participants with and without SMC, (b) participants with and without Obj-SCD, and (c) participants with overlapping or discrepant SMC and Obj-SCD classifications. Given the literature that both SMC and Obj-SCD may have utility as methods to capture the pre-MCI phase

along the AD clinical continuum, we hypothesized that SMC and Obj-SCD would be associated with greater tau burden relative to those without, and participants classified as both SMC and Obj-SCD would have the highest tau levels.

Methods

ADNI study

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by principal investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. For up-to-date information, see www.adni-info.org.

Participants

The enrollment criteria for ADNI have been previously described in detail [29]. ADNI was approved by the institutional review boards at each of the participating institutions. Written informed consent was obtained from all participants or authorized representatives at each site. The current study included 236 CU participants from ADNI 2 and 3 cohorts who had tau PET, Cognitive Change Index (CCI) [30], and neuropsychological data at their screening/baseline visit. ADNI 2 was the first cohort to include the CCI, which was used to define SMC.

SMC and Obj-SCD classifications

Participants who had an ADNI diagnosis of dementia or were classified as having mild cognitive impairment [29] based on the actuarial neuropsychological criteria at their baseline visit [31–33] were excluded. Among the participants who were considered CU, SMC was determined based on a score of ≥ 16 on the first 12 items of the CCI which is the threshold used for SMC in ADNI [30, 34]. The CCI is a self-reported measure of cognitive change, and the first 12 items are focused on memory changes.

Participants were considered to have Obj-SCD based on the following actuarial neuropsychological criteria: performed > 1 SD below the age-/education-/sex-adjusted mean on (a) 1 impaired total test score in 2 different cognitive domains (memory, language, attention/executive), (b) 2 impaired neuropsychological process scores from the Rey Auditory Verbal Learning Test (AVLT), or (c) 1 impaired total test score and 1 impaired process score [3, 4, 24]. The total test scores involved six neuropsychological test scores and, specifically, included two *memory* [AVLT delayed free recall correct responses and AVLT recognition discrimination (hits minus false

positives)], two *language* measures [30-item Boston Naming Test total correct or Multilingual Naming Test total correct and Animal Fluency total score], and two *attention/executive functioning* measures [Trail Making Test Parts A and B times to completion]. The three process scores for the Obj-SCD classification were calculated from the AVLT and included *total intrusion errors* (total non-target words said across all recall trials), *learning slope* [(trial 5 – trial 1)/5], and *retroactive interference* (trial 6/trial 5), all of which have been shown to differ between CU participants who remained stable and CU participants who progressed to MCI within 5 years of follow-up in ADNI [20].

Tau PET

PET imaging using flortaucipir (AV-1451) was used to quantify tau burden. The details of data acquisition and processing of ADNI flortaucipir PET data are available at adni.loni.usc.edu. A composite region of interest (ROI) that included regions representative of Braak stage III/IV pathology representing moderately progressed tau pathology was used [35]. Earlier Braak stages risk possible unreliable PET measurement given the susceptibility of circumscribed ROIs such as the entorhinal cortex and hippocampus to partial voluming and therefore were not examined in the current study [35]. Prior work has demonstrated that CU individuals who are A β -positive demonstrate greater tau levels in regions well beyond the medial temporal lobe, including the parietal regions, than individuals who were considered A β -negative [36], which supports the use of regions beyond the entorhinal cortex and hippocampus. Standardized uptake variable ratios (SUVRs) were calculated by dividing the SUV for each ROI by the inferior cerebellar gray, and values underwent partial volume correction using the geometric transfer method [37]. Given the non-normal distribution of the tau PET variable, both transformed and non-transformed models were examined. The results did not change, and therefore, the raw tau PET SUVR continuous variable was used in the primary models. In the follow-up analyses, tau was dichotomized and positivity was defined as Braak III/IV SUVR > 1.51 [38].

Demographics, clinical data, and covariates

Demographic data included participant age, sex, years of education, race, and ethnicity. Apolipoprotein E (APOE) positivity was defined as the presence of at least one $\epsilon 4$ allele. Vascular risk was measured using pulse pressure (systolic-diastolic blood pressure), which is a proxy measure for arterial stiffness [39]. Depressive symptoms were assessed using the Geriatric Depression Scale (GDS) score. ADNI only included participants with a baseline GDS < 6 ; thus, there was a limited range for this measure.

The Preclinical Alzheimer Cognitive Composite (PACC) score has been shown to detect early cognitive changes associated with AD-related pathology [40] and was used to compare the general cognitive performance across the groups. The ADNI-modified PACC included the Mini-Mental State Examination, Logical Memory Delayed Recall, Digit Symbol Substitution Test, and the Delayed Word Recall from the Alzheimer's Disease Assessment Scale–Cognitive Subscale. Each of the four component scores has a mean of 0 and a standard deviation of 1. Lower PACC scores represent lower performance. This cognitive measure was selected for the characterization of the groups since the individual measures included in the PACC do not overlap with any of the measures used for the actuarial classification of Obj-SCD.

A β PET was used to characterize the sample and was included as a covariate in follow-up analyses. Participants had either florbetapir ($n = 92$) or florbetaben ($n = 143$) PET scans that aligned with their tau PET scan (one participant had missing data). The details of data acquisition and processing of ADNI florbetapir PET and florbetaben PET data are available at adni.loni.usc.edu. A summary SUVR was calculated by dividing the mean uptake across 4 AD-vulnerable cortical regions (frontal, anterior/posterior cingulate, lateral parietal, and lateral temporal cortices) by whole cerebellar (white and gray matter) uptake. Greater retention of florbetapir or florbetaben is reflective of a greater cortical A β load. SUVR to centiloid transformations were then used to put both on a common metric [41]. A β positivity was defined using the established cutoffs of > 1.11 and > 1.08 for florbetapir and florbetaben, respectively [41].

Statistical analyses

Agreement in SMC and Obj-SCD classifications was measured using a kappa statistic. Unadjusted analyses of variance and chi-squared tests were used to examine the group differences in demographic and clinical data used for descriptive purposes. For the primary analyses, analyses of covariance, adjusting for age, sex, APOE $\epsilon 4$ status, and pulse pressure, examined the group differences in tau PET SUVR as a continuous variable. Three models were run that compared (1) SMC– and SMC+ participants, (2) Obj-SCD– and Obj-SCD+ participants, and (3) SMC–/Obj-SCD–, SMC+/Obj-SCD–, SMC–/Obj-SCD+, and SMC+/Obj-SCD+ participants. Given the small sample size of the overlapping and discrepant groups, an alpha of .05 was used throughout. Follow-up analyses including A β PET (centiloids) as a covariate were conducted to determine if the results are impacted when adjusting for cortical A β burden. Next, participants were then classified as tau positive (T+) or negative (T–) based on tau PET Braak stage III/IV SUVR. The

chi-squared models compared the proportions of T+ participants across the following groups: (1) SMC– and SMC+, (2) Obj-SCD– and Obj-SCD+, and (3) SMC–/Obj-SCD–, SMC+/Obj-SCD–, SMC–/Obj-SCD+, and SMC+/Obj-SCD+.

Results

Of the 236 participants, 159 (67.4%) were classified as SMC+ and 77 (32.6%) were classified as SMC–, whereas 63 (27.7%) participants were classified as Obj-SCD+ and 173 (73.3%) were classified as Obj-SCD–. Demographics and clinical data by SMC and Obj-SCD groups are shown in Table 1. Briefly, relative to participants without SMC, SMC+ participants had higher depressive symptoms (despite the limited range) and lower global cognition. Notably, there were no differences in PET A β levels or rates of A β positivity. Relative to participants without Obj-SCD, Obj-SCD+ participants had lower global cognition and higher tau PET, but also did not differ in PET A β levels or rates of A β positivity. CCI score (i.e., degree of SMC) did not differ between Obj-SCD+ and Obj-SCD– participants.

There was very little classification agreement between SMC and Obj-SCD ($\kappa = 0.008$, $p = .862$). There were 57 SMC–/Obj-SCD– participants, 116 SMC+/Obj-SCD– participants, 20 SMC–/Obj-SCD+ participants, and 43 SMC+/Obj-SCD+ participants. Demographics and clinical data by SMC and Obj-SCD agreement/discrepancy groups are shown in Table 2. Participants without SMC (SMC–/Obj-SCD– and SMC–/Obj-SCD+) had the lowest level of depressive symptoms, followed by SMC+/Obj-SCD–, and the SMC+/Obj-SCD+ group had the highest level of depressive symptoms. As expected, the SMC+ groups had higher scores on the CCI than the SMC– groups, and Obj-SCD+ groups had lower global cognition scores than the Obj-SCD– groups.

When comparing continuous tau PET across the groups, after adjusting for age, sex, APOE $\epsilon 4$ status, and pulse pressure, there were no tau PET differences between SMC+ and SMC– participants [$F(1, 230) = 0.77$, $p = .381$, $\eta_p^2 = .003$; see Fig. 1]. Conversely, Obj-SCD+ participants had higher tau PET SUVRs than Obj-SCD– participants [$F(1, 230) = 4.51$, $p = .035$, $\eta_p^2 = .019$]. These results did not change when A β PET was included as an additional covariate in these models.

Across the four overlapping/discrepant groups, the SMC–/Obj-SCD+ had the highest tau PET SUVRs and differed from participants in the SMC+/Obj-SCD– group ($p = .022$; see Fig. 2). The SMC–/Obj-SCD+ group marginally differed from participants in the SMC–/Obj-SCD– group ($p = .053$). Tau levels in the other groups did not differ from one another

Table 1 Baseline demographic and clinical characteristics of the SMC and Obj-SCD groups

	Total sample	SMC−	SMC+	F or χ^2	p	Obj-SCD−	Obj-SCD+	F or χ^2	p
N	236	77	159			173	63		
Age, mean (SD)	70.82 (6.24)	70.00 (5.59)	71.21 (6.52)	F = 1.96	0.162	70.80 (6.45)	70.88 (5.70)	F = 0.09	0.926
Education, mean (SD)	16.86 (2.21)	17.09 (2.10)	16.74 (2.25)	F = 1.30	0.256	16.81 (2.15)	16.98 (2.37)	F = 0.29	0.591
Female/woman, %	57.2%	59.7%	56.0%	$\chi^2 = 0.30$	0.584	59.5%	50.8%	$\chi^2 = 1.44$	0.230
Race, %				$\chi^2 = 6.32$	0.176			$\chi^2 = 2.75$	0.600
American Indian/Alaska Native	0.4%	1.3%	0.0%			0.6%	0.0%		
Asian	1.7%	1.3%	1.9%			1.2%	3.2%		
Black	3.0%	1.3%	3.8%			2.3%	4.8%		
White	92.4%	96.1%	90.6%			93.1%	90.5%		
More than one	2.5%	0.0%	3.8%			2.9%	1.6%		
Ethnicity, %				$\chi^2 = 2.98$	0.225			$\chi^2 = 2.24$	0.326
Hispanic/Latino	2.1%	0.0%	3.1%			2.9%	0.0%		
Non-Hispanic/non-Latino	97.5%	100%	96.2%			96.5%	100%		
Unknown	0.4%	0.0%	0.6%			0.6%	0.0%		
Pulse pressure, mean (SD)	55.40 (15.76)	57.09 (15.06)	54.58 (16.07)	F = 1.31	0.253	55.43 (15.20)	55.33 (17.35)	F = .002	0.968
APOE $\epsilon 4$ carrier, %	36.0%	29.9%	39.0%	$\chi^2 = 1.87$	0.171	37.0%	33.3%	$\chi^2 = 0.27$	0.604
GDS, mean (SD)	0.76 (1.11)	0.40 (0.67)	0.93 (1.24)	F = 12.24	< 0.001	0.71 (1.05)	0.89 (1.27)	F = 1.18	0.278
CCI, mean (SD)	19.65 (7.14)	13.56 (1.23)	22.60 (6.94)	F = 128.39	< 0.001	19.12 (6.63)	21.11 (8.24)	F = 3.65	0.057
PACC, mean (SD)	0.17 (2.82)	0.85 (2.69)	−0.15 (2.83)	F = 6.67	0.010	0.75 (2.36)	−1.40 (3.35)	F = 30.20	< 0.001
Tau PET, mean (SD)	1.43 (0.15)	1.44 (0.18)	1.43 (0.13)	F = 0.17	0.681	1.42 (0.13)	1.47 (0.19)	F = 4.03	0.046
A β PET ^a , mean (SD)	21.93 (30.46)	19.20 (28.26)	23.26 (31.49)	F = 0.92	0.340	21.69 (30.06)	22.58 (31.81)	F = 0.30	0.585
A β PET positivity, %	34.5%	29.9%	36.7%	F = 1.07	0.301	34.1%	35.5%	$\chi^2 = 0.04$	0.844

SMC subjective memory complaint, Obj-SCD objective subtle cognitive decline, APOE apolipoprotein E, GDS Geriatric Depression Scale, CCI Cognitive Change Index, PACC Modified Preclinical Alzheimer Cognitive Composite, Tau PET Braak III/IV SUVR, A β PET β -amyloid cortical SUVR in centiloids, F statistic reported for one-way ANOVAs, χ^2 statistic report for chi-square tests

^a 1 SMC+/Obj-SCD+ participant is missing A β PET data

(*p*-values > .213). The pattern of the results was the same when A β PET was included as a covariate in the models.

When participants were then classified as T+ or T−, 20.1% of SMC+ participants and 18.2% SMC− participants were T+ ($\chi^2 = 0.13$, *p* = .724). Conversely, 30.2% of Obj-SCD+ participants and 15.8% of Obj-SCD− participants were T+ ($\chi^2 = 6.23$, *p* = .013). T+ rates across the SMC−/Obj-SCD−, SMC+/Obj-SCD−, SMC−/Obj-SCD+, and SMC+/Obj-SCD+ groups were 10.5%, 18.1%, 40.0%, and 25.6%, respectively ($\chi^2 = 9.44$, *p* = .024). Relative to SMC−/Obj-SCD−, the SMC−/Obj-SCD+ (*p* = .003) and SMC+/Obj-SCD+ (*p* = .047) groups, but not the SMC+/Obj-SCD− (*p* = .197) group, had a greater proportion of T+ participants. T+ rates did not differ between SMC+/Obj-SCD+ and SMC+/Obj-SCD− (*p* = .296), nor between SMC+/Obj-SCD+ and SMC−/Obj-SCD+ (*p* = .246). SMC−/Obj-SCD+ participants had higher T+ rates than SMC+/Obj-SCD− participants (*p* = .027).

Discussion

Our study demonstrated that participants with Obj-SCD had a greater tau PET burden than participants without Obj-SCD, with a consistent pattern of results when examining tau both continuously as a Braak stage III/IV SUVR or discretely via rate of tau positivity. Conversely, neither continuous tau levels nor rates of tau positivity differed between participants with and without SMC. Contrary to our hypothesis, the combined SMC+/Obj-SCD+ group did not evince a greater tau PET burden relative to participants with only Obj-SCD. It was instead the SMC−/Obj-SCD+ group with the highest tau PET burden, despite the small sample size. Importantly, the rate of A β -positive participants did not differ between the groups, and the results were not changed when A β PET level (in centiloids) was considered in the models.

While several studies have examined the associations of SMC or the more broadly defined subjective cognitive decline construct with A β PET [5, 6, 9], fewer studies have examined the associations with tau PET. One

Table 2 Baseline demographic and clinical characteristics of the discrepant/overlapping group

	SMC−/Obj-SCD−	SMC+/Obj-SCD−	SMC−/Obj-SCD+	SMC+/Obj-SCD+	F or χ^2	p
N	57	116	20	43		
Age, mean (SD)	70.10 (5.51)	71.14 (6.86)	69.72 (5.94)	71.42 (5.56)	F = 0.69	0.560
Education, mean (SD)	17.16 (2.02)	16.64 (2.20)	16.90 (2.38)	17.02 (2.39)	F = 0.82	0.486
Female/woman, %	63.2%	57.8%	50.0%	51.2%	$\chi^2 = 1.91$	0.592
Race, %					$\chi^2 = 11.64$	0.475
American Indian/Alaska Native	1.8%	0.0%	0.0%	0.0%		
Asian	0.0%	1.7%	5.0%	2.3%		
Black	0.0%	3.4%	5.0%	4.7%		
White	98.2%	90.5%	90.0%	90.7%		
More than one	0.0%	4.3%	0.0%	2.3%		
Ethnicity, %					$\chi^2 = 6.37$	0.383
Hispanic/Latino	0.0%	4.3%	0.0%	0.0%		
Non-Hispanic/non-Latino	100.0%	94.8%	100.0%	100.0%		
Unknown	0.0%	0.9%	0.0%	0.0%		
Pulse pressure, mean (SD)	56.23 (12.80)	55.03 (16.29)	59.55 (20.38)	53.37 (15.61)	F = 0.77	0.512
APOE ϵ 4 carrier, %	29.8%	40.5%	30.0%	34.9%	$\chi^2 = 2.31$	0.511
GDS, mean (SD)	0.39 (0.68) ^{ac}	0.87 (1.16) ^d	0.45 (0.69) ^a	1.09 (1.43) ^{bd}	F = 4.52	0.004
CCI, mean (SD)	13.47 (1.20) ^{ac}	21.89 (6.45) ^{abd}	13.80 (1.32) ^{ac}	24.51 (7.89) ^{bcd}	F = 45.90	< 0.001
PACC, mean (SD)	1.39 (1.99) ^{abc}	0.43 (2.47) ^{ad}	− 0.71 (3.16) ^d	− 1.72 (3.15) ^{cd}	F = 12.67	< 0.001
Tau PET, mean (SD)	1.42 (0.13)	1.42 (0.13)	1.49 (0.28)	1.45 (0.13)	F = 1.61	0.187
A β PET ^e , mean (SD)	17.01 (27.30)	24.00 (31.18)	25.47 (30.69)	21.21 (32.60)	F = 0.77	0.512
A β PET positivity, %	26.3%	37.9%	40.0%	33.3%	F = 2.59	0.460

SMC subjective memory complaint, Obj-SCD objective subtle cognitive decline, APOE apolipoprotein E, GDS Geriatric Depression Scale, CCI Cognitive Change Index, PACC Modified Preclinical Alzheimer Cognitive Composite, Tau PET Braak III/IV SUVR, A β PET β -amyloid cortical SUVR in centiloids, F statistic reported for one-way ANOVAs, χ^2 statistic report for chi-square tests


^a Significantly different from SMC+/Obj-SCD+

^b Significantly different from SMC−/Obj-SCD+

^c Significantly different from SMC+/Obj-SCD−

^d Significantly different from SMC−/Obj-SCD−

^e 1 SMC+/Obj-SCD+ participant is missing A β PET data






Fig. 2 Braak III/IV SUVR by overlapping/discrepant SMC and Obj-SCD classifications. Dot-box plot shows residual Braak III/IV values by subjective memory complaint (SMC) and objective subtle cognitive decline (Obj-SCD) status. Covariates included age, sex, APOE $\epsilon 4$ carrier status, and pulse pressure. * $p < .05$

prior study demonstrated that entorhinal tau deposition was associated with greater severity of subjective cognitive decline [42]. In this study, global A β PET was also associated with subjective cognitive decline severity, but to a lesser degree. Within ADNI, another study examining the relationship between tau PET and subjective cognitive decline, using subscales from the Everyday Cognition (ECog) measure, showed that higher tau levels were associated with self-reported planning and visuospatial functioning, but not memory functioning [43]. Conversely, another study using ADNI data showed that the self-reported memory subscale from the ECog was associated with greater frontal tau burden, while the informant-reported memory subscale was associated with greater parietal tau burden [44]. While these studies have demonstrated some evidence of a relationship between subjective cognitive decline or SMC and tau, none of these studies examined a dichotomous subjective cognitive decline group. Although a continuous measure of subjective cognition is psychometrically advantageous, there may be less utility in the application of the results to the real world where dichotomous classifications may be particularly important for the purposes of clinical classification. Furthermore, it has been posited that the construct of subjective cognitive decline or SMC may be especially useful when screening for clinical trials [45], which would require a threshold or cut score for what is considered a meaningful report of cognitive decline. Importantly, while neither SMC nor Obj-SCD should

be used alone for clinical classification or clinical trial screenings at this time [46], it is valuable to understand how these classifications overlap or differ as well as relate to AD biomarkers and future progression so that we can continue to refine these approaches and ultimately gain the information needed to empirically support clinical methods for earlier detection.

Our current study chose to use the CCI to define SMC since this is the measure that ADNI uses to define SMC and has been shown to be associated with reduced gray matter [30], worse A β and cerebrospinal fluid tau markers (particularly in APOE $\epsilon 4$ carriers) [34], and faster cognitive decline relative to control participants [15]. There has been a significant effort, including the formation of the Subjective Cognitive Decline Initiative (SCD-I) working group, to define subjective cognitive decline, understand how measures of subjective cognitive decline/SMC overlap, and identify which measures are most useful [8, 17, 47, 48]. Given the many approaches to defining subjective cognitive decline/SMC, it is possible that the mixed results in the literature on SMC and AD biomarkers and future progression are due to the different approaches to defining the construct [15].

Other factors, such as the context of the study and how participants were recruited, have been shown to impact the utility of subjective cognitive decline for predicting future declines [13, 14]. Notably, despite none of the participants in this study meeting a cutoff for clinical depression levels, SMC participants had higher levels

of depressive symptoms than participants without SMC. It is difficult to disentangle whether people with higher depressive or anxiety symptoms are more likely to report SMC or whether these psychiatric symptoms and SMC emerge at a similar time due to very early AD-related changes. While the latter is possible, in this current study, participants with SMC did not have higher levels of A β or tau relative to those without SMC. It is possible that SMC is particularly inclusive and captures a heterogeneous group of both those with and without elevated AD biomarkers or risk for accelerated cognitive declines. Importantly, we are not proposing that the concept of SMC or subjective cognitive decline should be ignored. It should remain a key consideration in evaluations of older adults as it has been associated with faster declines in some samples [7, 13] and is consistently associated with lower quality of life [49], which is particularly deserving of attention.

To our knowledge, ours is the first study to examine tau PET in participants with Obj-SCD defined using sensitive neuropsychological scores. However, the results of our study are in line with prior work showing a 4-year trajectory of medial temporal lobe atrophy [3] and accelerated increases in plasma p-tau181 over time [24]. We had previously speculated that tau deposition was likely to precede neurodegeneration and was associated with the early cognitive changes observed in Obj-SCD [3]. While longitudinal tau PET studies are needed, the current study supports this hypothesis given that there were already mean differences in Braak III/IV tau levels between participants with and without Obj-SCD at their baseline visit. Furthermore, since there were no A β PET differences between the groups, it supports prior work showing that subtle cognitive changes can occur in the absence of or independent of A β [38, 50].

A strength of our current study is that actuarial neuropsychological criteria for MCI were used to exclude MCI participants [32, 33]. This approach to classifying MCI likely led to a more accurate pool of CU individuals from which to classify SMC and Obj-SCD given prior work showing that this approach leads to a more reliable MCI group [31, 32]. The neuropsychological measures used to define Obj-SCD require more training and time to administer than the single CCI questionnaire. The inclusion of multiple neuropsychological scores in the Obj-SCD criteria likely yielded a more reliable characterization of one's cognitive performance than the single measure of subjective memory changes. Future work may wish to examine whether an actuarial approach for SMC classification (i.e., that requires rating above a threshold on multiple SMC measures) improves reliability compared to a single cut score on one measure or composite score. Although it is possible that the SMC group is

capturing an "earlier" pre-MCI phase than the Obj-SCD group, and therefore does not have tau that has progressed to Braak stage III/IV, there were also no differences in A β burden between SMC- and SMC+ groups. Furthermore, there is evidence that cognitively unimpaired but A β -positive participants exhibit a widespread distribution of tau relative to A β -negative participants that extends beyond the medial temporal lobe, including to the lateral temporal lobe and parietal regions [36]. Therefore, it is likely that if the SMC group were accurately discriminating people on an AD trajectory, they would have at least a pattern for higher tau levels in limbic regions captured by Braak stages III/IV.

Limitations

A significant limitation of the current study is that the sample is not representative of the population or those most at-risk for AD given that it is predominately white, highly educated, and generally very healthy. Further work is needed to examine these relationships in more diverse cohorts, particularly since the Obj-SCD classification may have reduced utility for people for whom the neuropsychological measures were not originally validated given that many tests were initially developed and tested on white, educated volunteers. Another limitation of the study is the small number of participants with Obj-SCD but not SMC. While this group had the greatest tau burden, the results should be replicated in a larger sample. Longitudinal analyses comparing cognitive and biomarker trajectories of SMC and Obj-SCD are needed to make definitive conclusions related to whether one measure is more sensitive and reliable to capturing an earlier pre-MCI phase than the other, or if they are measuring different aspects of the pre-MCI phase.

Conclusions

In summary, our study shows that Obj-SCD, but not SMC, is associated with higher tau PET levels. There was very little classification agreement between Obj-SCD and SMC, and the addition of SMC to the Obj-SCD method did not improve the Obj-SCD association with the tau burden. These findings add to the existing evidence that the Obj-SCD classification is associated with AD biomarkers and faster cognitive decline in ADNI participants, but further work is needed to validate this classification approach in more representative/diverse cohorts before it can be applied in a clinical setting or as a tool for clinical trial screening.

Abbreviations

A β : β -Amyloid; AD: Alzheimer's disease; ADNI: Alzheimer's Disease Neuroimaging Initiative; APOE: Apolipoprotein E; AVLT: Rey Auditory Verbal Learning Test; CCI: Cognitive Change Index; CU: Cognitively unimpaired; ECog: Everyday

Cognition; GDS: Geriatric Depression Scale; Obj-SCD: Objective subtle cognitive decline; PACC: Preclinical Alzheimer's Cognitive Composite; PET: Positron emission tomography; ROI: Region of interest; SMC: Subjective memory complaint; SUVR: Standardized uptake variable ratio; T: Tau.

Acknowledgements

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

Authors' contributions

KRT conceptualized the study, obtained funding, analyzed and interpreted the data, prepared the figures, and drafted the manuscript. AJW and LCE obtained and analyzed the data. AJW, LCE, ECE, KJB, and MWB contributed to the study conceptualization. GO and KSW contributed to the data interpretation. All authors contributed to the writing and revisions of the paper and approved the final version. Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report.

Funding

This work was supported by the US Department of Veterans Affairs Clinical Sciences Research and Development Service (11K2CX001865, 1101CX001842, and 11K2CX001415), NIH/NIA grants (P30 AG062429, R03 AG070435, R01 AG063782, R01 AG049810, and R01 AG054049), and the Alzheimer's Association (AARF-17-528918, AARG-18-566254, and AARG-17-500358). Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Availability of data and materials

Alzheimer's Disease Neuroimaging Initiative data are available at <http://adni.loni.usc.edu/data-samples/access-data/> to anyone approved to access ADNI data. Derived data used during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by institutional review boards of all participating institutions, and written informed consent was obtained from all participants or their guardians according to the Declaration of Helsinki (consent for research).

Consent for publication

N/A.

Competing interests

Dr. Bondi receives royalties from Oxford University Press. The other authors declare that they have no competing interests.

Author details

¹Research Service, VA San Diego Healthcare System, Building 13, 3350 La Jolla Village Drive (151), San Diego, CA 92161, USA. ²Department of Psychiatry, University of California, La Jolla, San Diego, CA, USA. ³San Diego Joint Doctoral Program in Clinical Psychology, San Diego State University/University of California, San Diego, CA, USA. ⁴Banner Alzheimer's Institute, Tucson, AZ, USA. ⁵San Diego State University, San Diego, CA, USA. ⁶Psychology Service, VA San Diego Healthcare System, San Diego, CA, USA.

Received: 8 March 2022 Accepted: 9 August 2022

Published online: 22 August 2022

References

- Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 Study: stopping AD before symptoms begin? *Sci Transl Med*. 2014;6(228):228fs13.
- Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535–62.
- Thomas KR, Bangen KJ, Weigand AJ, Edmonds EC, Wong CG, Cooper S, et al. Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration. *Neurology*. 2020;94(4):e397–406.
- Thomas KR, Edmonds EC, Eppig J, Salmon DP, Bondi MW, Initiative ADN. Using neuropsychological process scores to identify subtle cognitive decline and predict progression to mild cognitive impairment. *J Alzheimers Dis*. 2018;64(1):195–204.
- Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorus N, Sullivan C, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. *Neuropsychologia*. 2012;50(12):2880–6.
- Buckley RF, Sikkes S, Villemagne VL, Mormino EC, Rabin JS, Burnham S, et al. Using subjective cognitive decline to identify high global amyloid in community-based samples: a cross-cohort study. *Alzheimers Dement*. 2019;11(C):670–8.
- Rabin LA, Smart CM, Amariglio RE. Subjective cognitive decline in preclinical Alzheimer's disease. *Annu Rev Clin Psychol*. 2017;13(1):369–96.
- Jessen F, Amariglio RE, van Bortel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimers Dement*. 2014;10(6):844–52.
- Chen X, Farrell ME, Moore W, Park DC. Actual memory as a mediator of the amyloid-subjective cognitive decline relationship. *Alzheimers Dement*. 2019;11:151–60.
- Kielb S, Rogalski E, Weintraub S, Rademaker A. Objective features of subjective cognitive decline in a United States national database. *Alzheimers Dement*. 2017;13(12):1337–44.
- Koppara A, Wagner M, Lange C, Ernst A, Wiese B, König HH, et al. Cognitive performance before and after the onset of subjective cognitive decline in old age. *Alzheimers Dement*. 2015;1(2):194–205.
- Bubbico G, Di Iorio A, Lauriola M, Sepede G, Salice S, Spina E, et al. Subjective cognitive decline and nighttime sleep alterations, a longitudinal analysis. *Front Aging Neurosci*. 2019;11:142.
- Snitz BE, Wang T, Cloonan YK, Jacobsen E, Chang CCH, Hughes TF, et al. Risk of progression from subjective cognitive decline to mild cognitive impairment: the role of study setting. *Alzheimers Dement*. 2018;14(6):734–42.
- Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, et al. Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. *Alzheimers Dement*. 2019;15(3):465–76.
- Morrison C, Dadar M, Shafiq N, Villeneuve S, Louis CD. Regional brain atrophy and cognitive decline depend on definition of subjective cognitive decline. *NeuroImage Clin*. 2022;33:102923.

16. Zlatar ZZ, Muniz MC, Espinoza SG, Gratianna R, Gollan TH, Galasko D, et al. Subjective cognitive decline, objective cognition, and depression in older Hispanics screened for memory impairment. *J Alzheimers Dis*. 2018;63(3):949–56.
17. Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. *Lancet Neurol*. 2020;19(3):271–8.
18. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol*. 2010;9(1):119–28.
19. Jedynak BM, Lang A, Liu B, Katz E, Zhang Y, Wyman BT, et al. A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease neuroimaging initiative cohort. *NeuroImage*. 2012;63(3):1478–86.
20. Thomas KR, Eppig J, Edmonds EC, Jacobs DM, Libon DJ, Au R, et al. Word-list intrusion errors predict progression to mild cognitive impairment. *Neuropsychology*. 2018;32(2):235–45.
21. Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Subtle cognitive decline and biomarker staging in preclinical Alzheimer's disease. *J Alzheimers Dis*. 2015;47(1):231–42.
22. Thomas KR, Bangen KJ, Weigand AJ, Edmonds EC, Sundermann E, Wong CG, et al. Type 2 diabetes interacts with Alzheimer disease risk factors to predict functional decline. *Alzheimer Dis Assoc Disord*. 2020;34(1):10–7.
23. Thomas KR, Osuna JR, Weigand AJ, Edmonds EC, Clark AL, Holmqvist S, et al. Regional hyperperfusion in older adults with objectively-defined subtle cognitive decline. *J Cereb Blood Flow Metab*. 2021;41(5):1001–12.
24. Thomas KR, Bangen KJ, Edmonds EC, Weigand AJ, Walker KS, Bondi MW, et al. Objective subtle cognitive decline and plasma phosphorylated tau181: early markers of Alzheimer's disease-related declines. *Alzheimers Dement*. 2021;13(1):e12238.
25. Cui L, Zhang Z, Zac Lo CY, Guo Q. Local functional MR change pattern and its association with cognitive function in objectively-defined subtle cognitive decline. *Front Aging Neurosci*. 2021;13:684918.
26. Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. *Neurology*. 2018;91(9):e859–66.
27. Bucci M, Chiotis K, Nordberg A. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. *Mol Psychiatry*. 2021;26(10):5888–98.
28. Snitz BE, Brickman AM. Do subtle cognitive deficits precede amyloid accumulation?: Cart before the horse. *Neurology*. 2020;94(4):151–52.
29. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization. *Neurology*. 2010;74(3):201–9.
30. Saykin AJ, Wishart HA, Rabin LA, Santulli RB, Flashman LA, West JD, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnesic MCI. *Neurology*. 2006;67(5):834–42.
31. Thomas KR, Edmonds EC, Eppig JS, Wong CG, Weigand AJ, Bangen KJ, et al. MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative. *Alzheimers Dement*. 2019;15(10):1322–32.
32. Bondi MW, Edmonds EC, Jak AJ, Clark LR, Delano-Wood L, McDonald CR, et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. *J Alzheimers Dis*. 2014;42(1):275–89.
33. Jak AJ, Bondi MW, Delano-Wood L, Wierenga C, Corey-Bloom J, Salmon DP, et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. *Am J Geriatr Psychiatry*. 2009;17(5):368–75.
34. Risacher SL, Kim S, Nho K, Foroud T, Shen L, Petersen RC, et al. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. *Alzheimers Dement*. 2015;11(12):1417–29.
35. Landau S, Ward TJ, Jagust WJ. Flortaucipir (AV-1451) processing methods. 2021. Available from: <http://adni.loni.usc.edu/>.
36. Schultz SA, Gordon BA, Mishra S, Su Y, Perrin RJ, Cairns NJ, et al. Wide-spread distribution of tauopathy in preclinical Alzheimer's disease. *Neurobiol Aging*. 2018;72:177–85.
37. Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data. *Data Brief*. 2017;15:648–57.
38. Weigand AJ, Bangen KJ, Thomas KR, Delano-Wood L, Gilbert PE, Brickman AM, et al. Is tau in the absence of amyloid on the Alzheimer's continuum?: a study of discordant PET positivity. *Brain Commun*. 2020;2:fcz046.
39. Nation DA, Edmonds EC, Bangen KJ, Delano-Wood L, Scanlon BK, Han SD, et al. Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. *JAMA Neurol*. 2015;72(5):546–53.
40. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The Preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline. *JAMA Neurol*. 2014;71(8):961–70.
41. Royse SK, Minhas DS, Lopresti BJ, Murphy A, Ward T, Koeppe RA, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. *Alzheimers Res Ther*. 2021;13(1):99.
42. Buckley RF, Hanseeuw B, Schultz AP, Vannini P, Aghjayan SL, Properzi MJ, et al. Region-specific association of subjective cognitive decline with tauopathy independent of global β -amyloid burden. *JAMA Neurol*. 2017;74(12):1455–63.
43. Shokouhi S, Conley AC, Baker SL, Albert K, Kang H, Gwirtsman HE, et al. The relationship between domain-specific subjective cognitive decline and Alzheimer's pathology in normal elderly adults. *Neurobiol Aging*. 2019;81:22–9.
44. Swinford CG, Risacher SL, Charil A, Schwarz AJ, Saykin AJ. Memory concerns in the early Alzheimer's disease prodrome: regional association with tau deposition. *Alzheimers Dement*. 2018;10:322–31.
45. Buckley RF, Villemagne VL, Masters CL, Ellis KA, Rowe CC, Johnson K, et al. A conceptualization of the utility of subjective cognitive decline in clinical trials of preclinical Alzheimer's disease. *J Mol Neurosci*. 2016;60(3):354–61.
46. Petersen RC, Wiste HJ, Weigand SD, Fields JA, Geda YE, Graff-Radford J, et al. NIA-AA Alzheimer's Disease Framework: clinical characterization of stages. *Ann Neurol*. 2021;89(6):1145–56.
47. Rabin LA, Smart CM, Crane PK, Amariglio RE, Berman LM, Boada M, et al. Subjective cognitive decline in older adults: an overview of self-report measures used across 19 international research studies. *J Alzheimers Dis*. 2015;48(s1):S63–86.
48. Tandetnik C, Farrell MT, Cary MS, Cines S, Emrani S, Karlawish J, et al. Ascertain subjective cognitive decline: a comparison of approaches and evidence for using an age-anchored reference group. *J Alzheimers Dis*. 2015;48(s1):S43–55.
49. Hill NL, McDermott C, Mogle J, Munoz E, DePasquale N, Wion R, et al. Subjective cognitive impairment and quality of life: a systematic review. *Int Psychogeriatr*. 2017;29(12):1965–77.
50. Maass A, Lockhart SN, Harrison TM, Bell RK, Mellinger T, Swinnerton K, et al. Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging. *J Neurosci*. 2018;38(3):530–43.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

